Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adalgisa Condoluci

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
American Journal of Hematology|April 17, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, et al.
Hematological Oncology|May 25, 2022
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemiaGabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, et al.
Blood|February 17, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphomaValeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Leukemia|April 15, 2020
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyMassimo Gentile, Fortunato Morabito, Giovanni Del Poeta, et al.
Hemasphere|July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experienceRiccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
Swiss Medical Weekly|October 25, 2021
Management of transthyretin amyloidosisAdalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, et al.
American Journal of Hematology|February 13, 2021
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL studyFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|May 14, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
American Journal of Hematology|April 17, 2023
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, et al.
Hematological Oncology|May 25, 2022
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemiaGabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, et al.
Blood|February 17, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphomaValeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Leukemia|April 15, 2020
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyMassimo Gentile, Fortunato Morabito, Giovanni Del Poeta, et al.
Hemasphere|July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experienceRiccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
Swiss Medical Weekly|October 25, 2021
Management of transthyretin amyloidosisAdalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, et al.
American Journal of Hematology|February 13, 2021
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL studyFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|May 14, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Pageof 5